evaluating the patient with abnormal liver tests-2
DESCRIPTION
Evaluating the Patient With Abnormal Liver Tests-2. פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים. Imaging studies. Abdominal Ultrasound with Doppler of hepatic and portal veins Abdominal MRCP Upper endoscopy (EGD) Liver biopsy Non Invasive Tests for Fibrosis. Imaging studies-1. - PowerPoint PPT PresentationTRANSCRIPT
Evaluating the Patient With Abnormal Liver Tests-2
פרופ' צבי אקרמן מבית חולים הדסה הר הצופים
Imaging studies
• Abdominal Ultrasound with Doppler of hepatic and portal veins
• Abdominal MRCP
• Upper endoscopy (EGD)
• Liver biopsy
• Non Invasive Tests for Fibrosis
Imaging studies-1
• Abdominal Ultrasound with Doppler of hepatic and portal veins-1
• Abdominal ultrasound is helpful in the evaluation of patients with cirrhosis.
• It may reveal a shrunken, nodular liver suggestive of cirrhosis.
Imaging studies-1a1a
• The liver may appear echogenic if excessive fat has infiltrated the liver as in NAFLD (nonalcoholic fatty liver disease).
• It is sensitive for the detection of small to moderate amounts of ascites.
• It can be used to screen for liver masses which may suggest the presence of hepatocellular carcinoma.
Imaging studies-2
• Abdominal Ultrasound with Doppler of hepatic and portal veins-2
• The use of Doppler ultrasonography can provide information about the hepatic and portal veins such as portal vein thrombosis.
• Because it is relatively inexpensive, and widely available, ultrasonography is the preferred initial imaging modality in patients with cirrhosis.
Imaging studies-3
• Abdominal MRCP
• MRI is not indicated in every evaluation of liver disease , only in cases where specific bile duct pathology is suspected.
• It is expensive and ‘simple”information can be obtained with ultrasonography.
Imaging studies-4
• Upper endoscopy (EGD)
• Upper endoscopy is useful in the diagnosis of esophageal varices, a finding seen with portal hypertension.
• In cirrhotic patients, it is useful to document the presence of varices so prophylactic measures can be instituted to decrease the risk of bleeding.
Imaging studies-3
Imaging studies-3
Imaging studies • Abdominal Ultrasound with Doppler of hepatic and
portal veins
• Abdominal MRCP
• Upper endoscopy (EGD)
• Liver fibrosis Assessment :Liver biopsy
• Liver fibrosis Assessment :Non Invasive Tests for Fibrosis
Liver Biopsy
Hepatic Injury : Hepatic Injury : necrotico-inflammatory activity, necrotico-inflammatory activity, fibrosis, fibrosis, steatosis, steatosis, biliary lesions, vascular lesionsbiliary lesions, vascular lesions
Fibrosis scores Fibrosis scores ( METAVIR, Knodell , Ishak,…)( METAVIR, Knodell , Ishak,…)
Invasive procedure Invasive procedure morbidity : 0.3 to 0.6% morbidity : 0.3 to 0.6% mortality : 0 to 0.05% mortality : 0 to 0.05%
Cost : approximately 4000 NIS ( without complications)Cost : approximately 4000 NIS ( without complications)
F1
F4
F2
F1
F4
Imaging studies
BioMarkers of liver injury
• Markers of Fibrosis
• Scores of Fibrosis
Hem orrhage Liver Failure Cancer
F4
F3
F2
F1
F0
Fibrotic LiverDisease
How must be an ideal marker of liver Fibrosis?
• Specific to the Liver
• Independant to metabolic dysfunction
• Easy to perform
• Sensitivity to detect the different stages of liver fibrosis
• Can reliably assess the efficacy of antifibrotic treatment
• Can be used whatever the etiology of chonic liver fibrosis
• Non influenced by extra-hepatic factors
Haptoglobin
Alpha2Macroglobulin
Apolipoprotein A1
Total Bilirubin
Gamma GT
In Situ In Serum: FibroTestIn Serum: FibroTest
Liver InjuryLiver Injury
Activated Stellate CellsActivated Stellate Cells
Fibrotic MatrixFibrotic Matrix
ALT
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 1 2 3 4
FibroTest
METAVIR Fibrosis Stage
Multicenter Independant ValidationHalfon, Am J Gastroenterol 2006
n=519
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4
Fibrosis Stage
Fib
rote
stDisease
HBVHCVHCV_HIVNAFLDOH
Myers et al 2003
Poynard et al 2004
Myers et al 2003
Ratziu et al 2004
Naveau et al 2005
FibroFibroTestTest: fibrosis marker in other chronic : fibrosis marker in other chronic liver diseases (n=2,706)liver diseases (n=2,706)
LONGITUDINAL STUDIES
The Fibrotest was found to predict the evolution of HCV patients towards cirrhosis better than liver biopsy after 5 years of follow-upNgo Clin Chem 2006
Progression of liver fibrosis
0
1
2
3
4
0 10 20 30 40 50
F METAVIR
Duration in years
Rapid Intermediate
Slow fibroser
Poynard et al
Abnormal Liver Test Results: Points for Clinical Practice• Abnormal liver test results will be identified in 8%-20% of patients during
clinical care.
• Most patients with abnormal liver test results should have additional evaluation. A referral to the gastroenterologist may be needed.
• A careful history and physical examination frequently provide the diagnosis, obviating the need for invasive testing.
• If there are signs or symptoms of chronic liver disease, considering the patient's age may assist in the diagnosis.
• Isolated elevation of GGT occurs and a cause may not be identified.
CON-Abnormal Liver Test Results: Points for Clinical Practice
• The presence of multiple abnormal test results makes significant liver disease more likely.
• Aminotransferase, alkaline phosphatase, and GGT levels can be elevated from causes other than liver disease.
• Persisting abnormalities of aminotransferases or enzymes of cholestasis should be further evaluated because up to two thirds will have a diagnosis requiring follow-up or intervention.
• Supplemental testing with additional laboratory tests, ultrasonography, or magnetic resonance cholangiography should be considered when the diagnosis is unclear or confirmation of liver disease diagnosis is required.
תודה רבה על ההקשבה